Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00539006 · ClinicalTrials.gov registry record · Phase 4

Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS

A Phase 4 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
377
Enrollment target

NCT00539006: Completed Phase 4 study, sponsored by GlaxoSmithKline.

NCT00539006 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 377 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00539006, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
377 participants
Enrollment target

Study Summary

The purpose of this replicate study to FFU105927 is to provide data on subject preference of FFNS as compared with FPNS.

Primary Outcome

Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.

Interventions

  • DRUG FPNS
  • DRUG FFNS
  • DRUG placebo FPNS
  • DRUG placebo FFNS

Trial Details

FieldValue
Enrollment Target 377 participants
Start Date 2007-08
Est. Completion 2007-11
Phase Phase 4
GlaxoSmithKline

1,345 total trials

What the finished NCT00539006 record still lists

NCT00539006 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (27% lower).

The record links to 0 conditions, and to 4 interventions - of which FPNS is the first listed.

NCT00539006 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00539006 about?

NCT00539006 is a clinical study titled "Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS". The purpose of this replicate study to FFU105927 is to provide data on subject preference of FFNS as compared with FPNS.

What is the current status of trial NCT00539006?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 377 participants. The study started on 2007-08. Estimated completion is 2007-11.

What interventions are being tested in trial NCT00539006?

The interventions under investigation include: FPNS (DRUG), FFNS (DRUG), placebo FPNS (DRUG), placebo FFNS (DRUG).

Who is sponsoring clinical trial NCT00539006?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00539006's enrollment target sits among peer trials

377 222nd of 2000 higher than 1,779 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07024784 · 377 participants · Phase 2

    A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • NCT04254185 · 378 participants · NA

    Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

  • NCT06616584 · 378 participants · Phase 2

    Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • NCT03102125 · 376 participants · Phase 4

    Allograft Dysfunction in Heart Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00539006, the US trial registry maintained by the National Library of Medicine. NCT00539006 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.